# WORLD TRANSPLANTATION

Voice

# WORLD TRANSPLANTATION

Proceedings
of the Twelfth International Congress
of the Transplantation Society

August 14-19, 1988, Sydney, Australia

#### **Editors**

### A. G. Ross Sheil

Department of Surgery The University of Sydney Sydney, Australia

and

# Felix T. Rapaport

Department of Surgery
State University of New York at Stony Brook
Stony Brook, New York, USA



APPLETON & LANGE

Norwalk, Connecticut/San Mateo, California

World Transplantation is the hardcover edition of the February 1989 issue (Volume XXI, Number 1) of the bimonthly journal Transplantation Proceedings, an official publication of the Transplantation Society.

### 0-8385-9773-4

Notice: The author(s) and publisher of this volume have taken care that the information and recommendations contained herein are accurate and compatible with the standards generally accepted at the time of publication.



Copyright © 1989 by Appleton & Lange A Publishing Division of Prentice Hall

All rights reserved. This book, or any parts thereof, may not be used or reproduced in any manner without written permission. For information, address Appleton & Lange, 24 Van Zant Street, East Norwalk, Connecticut 06855.

89 90 91 92 93 / 10 9 8 7 6 5 4 3 2 1

Prentice Hall International (UK) Limited, London Prentice Hall of Australia Pty. Limited, Sydney

Prentice Hall Canada, Inc., Toronto

Prentice Hall Hispanoamericana, S.A., Mexico

Prentice Hall of India Private Limited, New Delhi

Prentice Hall of Japan, Inc., Tokyo

Simon & Schuster Asia Pte. Ltd., Singapore

Editora Prentice Hall do Brasil Ltda., Rio de Janeiro

Prentice Hall, Englewood Cliffs, New Jersey

89-080610

Managing Editor: Michele Jarmak

PRINTED IN THE UNITED STATES OF AMERICA

# **ACKNOWLEDGMENTS**

The Twelfth International Congress of the Transplantation Society is sponsored by:

The Transplantation Society

The Transplantation Society of Australia and New Zealand

The Local Organizing Committee wishes to thank the following organizations for support:

The National Heart Foundation of Australia

The Australian Cancer Society Incorporated

The Royal Australian College of Ophthalmologists

The Council of the City of Sydney

The Local Organizing Committee wishes to thank the major sponsors, Sandoz Limited, Basle; Sandoz Incorporated, USA; and Sandoz Australia Pty. Ltd. for their generous support.

The Local Organizing Committee also wishes to thank the following Corporations for sponsorship:

Ortho Pty Ltd (USA)

Cilag Pty Ltd, Australia

WL Gore & Associates (Australia) Pty Ltd

Burroughs Wellcome Co., USA

Wellcome Research Laboratories, UK

Wellcome Australia Ltd

Upjohn Pty Ltd (USA)

Upjohn Pty Ltd, Australia

Baxter Centre for Medical Research, Pty Ltd

Johnson and Johnson Pty Ltd, Australia

Tubemakers Finance Ltd, Australia

Gambro Pty Ltd, Australia

Pfizer Pty Ltd, Australia

Sterling-Winthrop Research Institute, Division of Sterling Drug Inc., USA

# TWELFTH INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY

August 14-19, 1988 Sydney, Australia

PATRON: His Excellency The Right Honourable

Sir Ninian Stephen, A.K., G.C.M.G., G.V.C.O., K.B.E. Governor-General of the Commonwealth of Australia

#### OFFICERS OF THE TRANSPLANTATION SOCIETY

President: Anthony P. Monaco

President-Elect: J. Richard Batchelor

Vice-Presidents: Israel Penn

Erik Thorsby

Secretaries: (Western) Mary L. Wood

(Eastern) Richard F.M. Wood

Treasurers: (Western) Felix T. Rapaport

(Eastern) Alan Ting

#### Councillors

Robert Corry Robert A. Sells
Ronald Guttmann Calvin Stiller

Mark Hardy Rainer Storb
Erna Moller Samuel Strober

Gerhard Opelz
Oscar Salvatierra

Sainted Street
Nicholas L. Tilney
Frank J. Veith

Immediate Past President: Peter J. Morris

#### **Past Presidents**

Bernard Amos Sir Michael Woodruff

Sir Peter Medawar Rubert E. Billingham

John M. Converse Leslie Brent
Jean Hamburger Felix T. Rapaport

Paul S. Russell Hans Balner

Paul I. Terasaki

#### LOCAL ORGANIZING COMMITTEE

Chairman: A.G. Ross Sheil

Secretary: John F. Thompson

#### **Members**

Richard Allen
Kerry Atkinson
James Biggs
Graeme Stewart
Robert Burton
Victor Chang
Jeremy Chapman
Bruce Hall (Secretary/Treasurer until July 1987)

#### **General Committee**

Tony d'Apice Priscilla Kincaid-Smith
Robert Atkins Ian McKenzie
Frank Christiansen Gordon Clunie Vernon Marshall
Ian Hardie Tim Mathew
Tony House Sir Gustav Nossal

**David Scott** 

#### INTERNATIONAL ABSTRACT SELECTION COMMITTEES

#### Category A—Immunobiology

F.H. Bach, United States J.R. Batchelor, United Kingdom L. Brent, United Kingdom T.J. Gill, United States B.M. Hall, United States P. Hayry, Finland

I.F.C. McKenzie, Australia

F. Milgrom, United States B.J. Roser, United Kingdom

P.S. Russell, United States

D. Steinmuller, United States

G.J. Stewart, Australia

T.B. Strom, United States

J.M. Thomas, United States

#### Category B-Immunogenetics and Histocompatibility

E. Albert, West Germany J.R. Chapman, Australia F.T. Christiansen, Australia A.J.F. d'Apice, Australia

J.A. Falk, Canada

F. Kissmeyer, Denmark

E. Moller, Sweden

G. Opelz, West Germany

P.I. Terasaki, United States

E. Thorsby, Norway

A. Ting, United Kingdom

J.J. Van Rood, The Netherlands

#### Category C—Immunosuppression

R.Y. Calne, United Kingdom A.B. Cosimi, United States R.N. Fine, United States A.K. House, Australia O. Jonasson, United States

B.D. Kahan, United States

R.R. Lower, United States

T.M. Mathew, Australia

P.J. Morris, United States

J.A. Myburgh, South Africa

C.R. Stiller, Canada

J.F. Thompson, Australia

N.G. Tufveson, Sweden D.J.G. White, United Kingdom

# Category D—Transplantation of Tissues and Organs (Kidney)

G.P.J. Alexandre, Belgium

J.D. Briggs, United Kingdom

P.A. Keown, Canada

W. Land, West Germany J.F. Mahony, Australia

F.T. Rapaport, United States

J.R. Salaman, United Kingdom

R.A. Sells, United Kingdom

R.L. Simmons, United States J.H. Stewart, Australia

N.L. Tilney, United States

G.M. Williams, United States

R.F.M. Wood, United Kingdom

I. Hardie, Australia

#### Category E—Transplantation of Tissues and Organs (Other Organs) LIVER

N.L. Ascher, United States

B.W. Shaw Jr, United States

H. Bismuth, France

A.G.R. Sheil, Australia

T.E. Starzl, United States

#### HEART, HEART/LUNG, LUNG

J.D. Cooper, Canada

T.A.H. English, United Kingdom

B.A. Reitz, United States P. Spratt, Australia

D. Novitzky, United States

F.J. Veith, United States

#### PANCREAS, ISLETS OR FOETAL PANCREAS

R.D.M. Allen, Australia

C.G. Groth, Sweden

R.J. Corry, United States

D.E.R. Sutherland, United States

J.M. Dubernard, France

T.E. Mandel, Australia

B.E. Tuch, Australia

#### Category F—Bone Marrow Transplantation

K.A. Atkinson, Australia

J.C. Briggs, Australia

R.P. Gale, United States

E. Gluckman, France

J.M. Goldman, United Kingdom

A.D. Hess, United States

R.J. O'Reilly, United States

R.L. Powles, United Kingdom

G.W. Santos, United States

S. Slavin, Israel

R. Storb, United States

P.J. Tutschka, United States

# WELCOME FROM THE PRESIDENT OF THE TRANSPLANTATION SOCIETY

It gives me great pleasure to welcome you on behalf of the Council of the Transplantation Society to the Twelfth International Congress of the Transplantation Society. This is the first time the Western Hemisphere Congress has been held outside the United States, and we are all especially pleased that the exciting and vital city of Sydney has been selected as the venue for this Congress.

Over the past several years the growth in knowledge of transplantation immunobiology and the clinical application of organ transplantation has been exponential. This expansion in knowledge and activity makes this Congress especially important to define, identify, and clarify areas of progress, as well as problems toward which we should focus our attention. To this end, Professor A.G. Ross Sheil and his Local Organizing Committee have prepared an extraordinary program that covers the latest advances and current status of all aspects of transplantation and related immunobiology. Equal emphasis has been placed on basic science advances and the latest clinical application of organ transplantation. Material from over 1600 submitted abstracts has been used as the basis for this extraordinary program.

An additional feature of the Twelfth International Congress is that it is being held in Sydney during Australia's 200th birthday anniversary. This is a unique time to visit this special country and to enjoy the warm and gracious hospitality of the Australian government and the Australian people.

Anthony P. Monaco, M.D.

President, The Transplantation Society.

# WELCOME FROM THE LOCAL ORGANIZING COMMITTEE

The Local Organizing Committee welcomes you warmly to Sydney. This is the first occasion that the Biennial Congress has been held in Australia or in the Southern Hemisphere. We are a little sad that the traditional Congress month of August is one of the Southern Hemisphere winter months. We would much have preferred you to enjoy our country in the Spring, Summer or Autumn.

Our attempt to move the Congress into the Australian Springtime in September was ill-fated. The dates originally (in 1984) chosen for the Congress were in September 1988 and it eventuated that they coincided with the 1988 Jewish High Holy Days. This became known to us in 1986 and it was necessary to revert to the August dates, as, by the time the error had been discovered and because of heavy bookings resulting from the Australian Bicentennial celebrations, the only available dates remaining in 1988 were in August.

For a time, the change of Congress dates from September seemed beneficial in an unexpected way. We learned that an exciting new Convention Center was to be built in the Darling Harbour area of Sydney. The completion date was to be in January 1988, and the Center would be opened as part of the Australian Bicentenary Celebrations. With delight we booked in here for the International Congress in August. However, this was not to be. We monitored the building process closely but it became progressively more obvious that the opening date for the new Convention Center would not be met and that the possible opening was moving closer and closer to our Congress dates. Finally, by the end of 1987, we determined that the Congress would have to be held in our backup facilities which are at the Convention Area of Centrepoint and the State Theatre. Even so, Registrants at the Twelfth International Congress will experience the new Darling Harbour complex as two of the important Congress functions are to take place there. We shall do our utmost to see that registrants do not become confused between the two areas. Please note that the Twelfth International Congress is NOT sited in Darling Harbour. It is sited at the Convention Area of Centrepoint and the State Theatre in Sydney City.

The prime objective of your Local Organizing Committee was to plan a Congress of the highest scientific standard. To this end, we have invited 80 leading authorities in all the disciplines related to transplantation biology and clinical practice to address the Congress in Plenary and Symposium Sessions. We have done our best to eliminate duplication or unnecessary overlap of presentations. The Plenary Sessions for the first four days review the advancing frontiers of transplantation biology. The Plenary Sessions on the closing day of the Congress present the "State of the Art" of clinical transplantation. The speakers in these Sessions have been given the difficult job of including an assessment of presentations at Congress. We are indebted to Professor Sir Gustav Nossal for agreeing to address the registrants in the closing Plenary Session. On all mornings of the Congress, the Symposium sessions highlight the topics of greatest general interest in each of the various sections.

The Committee also has cautiously taken the step of providing parallel sessions each day in the various sections within transplantation immunology and practice. We believe that by providing sessions for each of the research or clinical sections on each day, the Congress will continue to be the major forum for presentation for all the sections. That is, we have endeavored to provide daily involvement for clinicians and scientists primarily committed in the areas of immunobiology, tissue matching, immunosuppression and of the organs kidney, liver, heart, heart/lung and lung, pancreas, pancreatic islets and bone marrow. We have included areas of evolving transplantation and transplantation within the central nervous system and of peripheral nerves. We have done this in the full recognition that there will be many clashes of interests for the registrants. We can do nothing but apologize for this but remain optimistic that all registrants will be fully occupied each day with sessions of prime interest for each individual.

There were a record 1597 abstracts submitted for consideration. These were judged by the International Abstract Selection Committee. In all, 1427 (89%) abstracts were selected, 467 for oral presentation and 970 for Poster presentation. However, it must be realized that the abstracts selected for oral presentation were not always selected according to the overall rating of the International Abstract Selection Committee; some of the abstracts selected for presentation in less commonly grafted organs rated less well than did many abstracts submitted in the areas of commonly transplanted organs. Even so, the Committee decided that selection to fill out all the sessions was preferable to the provision of multiple concurrent sessions involving the most common organs and resulting in impossible clashes. That is, we felt that registrants could only physically be in one place at one time.

The net result is that the Posters are the major form of communication at this Congress. We have provided generous times for poster viewing. Each poster will be mounted for at least two full days of the Congress.

There was another important aspect to our planning. From the inception, we aimed to ensure a large registration and to meet what we believe is one of the prime functions of the Biennial International Congresses, to promote social interaction between the registrants. We recognized that the International Congresses provide rare opportunities for many Society members, particularly younger members and those from developing countries, to meet with each other and with the other Society

members including leaders in the various fields. We also knew that the cost of the social functions has sometimes meant that many registrants have not attended these events. For these reasons we pursued an active publicity campaign, kept the Congress registration fees as low as possible, and included as many social events as could be managed within the registration fees.

Other decisions of the Local Organizing Committee relate to the Pre-Congress Educational Course and the Post-Congress Workshop on Organ Preservation and Immunosuppression. The bringing together of world authorities in all the different areas seemed too good a chance to miss for an educational course. The Pre-Congress Educational Course on all aspects of tissue and organ transplantation is exciting and has been well subscribed. The presentations will be published. The Local Organizing Committee thanks the world leaders presenting at this Course, all of whom are doing this in an honorary capacity. We also planned the Post-Congress Workshops to be in North Queensland so that those registrants involved in the disciplines of immunosuppression and organ preservation (that is, the great majority of registrants) would, at the same time as consolidating and advancing knowledge in these areas, have the opportunity to visit and see the wonders of the Australian Great Barrier Reef and of our tropical rainforests.

So now the work is done. The Local and General Organizing Committees thank wholeheartedly the members of the International Abstract Selection Committee for their prompt assessment of the abstracts; also, Mr Charles Page of the Computer Department at St Mary's Hospital in London for analysis of the marks. We are grateful to the Societies, Foundations and Corporations for their support of the International Congress and in particular the Sandoz Company in Switzerland, the United States of America and Australia who were our major sponsors. We also pay tribute to the help and interest afforded by the President of the Society, A.P. Monaco, the Secretaries M.L. Wood and R.F.M. Wood, the Treasurers F.T. Rapaport and A. Ting and, through them, the Councillors.

As far as we can judge the scientific aspects of the Congress will be of the highest standard. Just as this will be determined by the registrants, so will the enjoyment of the social functions. We have set the scene and now hand over to you, the registrants, to ensure that the Twelfth International Congress is memorable.

#### **AGR Sheil**

On behalf of The Local and General Organizing Committees.

#### Book I

	Foreword		
		IMMUNOBIOLOGY OF TRANSPLANTATION	
	1.	A. Immunopathology	
		B. Lymphokines	
		C. Cell-surface Molecules	
		D. Mechanisms of Immunobiological Reactions	
		E. The Thymus	
		F. Suppressor Cells and Factors	
		G. Kidney	
		1. Immunopathology	
		2. Lymphokines	
		3. Cell-surface Molecules	
		4. Mechanisms of Immunological Reactions	
		5. Suppressor Cells and Factors	
		6. Antigenic Modulation, Enhancement, and Tolerance	
		H. Liver	
		1. Immunopathology	
		2. Mechanisms of Immunological Reactions	
		3. Suppressor Cells and Factors	
		I. Heart, Heart/Lung, and Lung	
		1. Immunopathology	
		2. Lymphokines	
		3. Cell-surface Molecules	
		4. Mechanisms of Immunological Reaction	
		5. Suppressor Cells and Factors	
		6. Antigenic Modulation, Enhancement, and Tolerance	
		7. Sensitization and Tolerance	
		J. Pancreas	
		1. Immunopathology	
		2. Lymphokines	
		3. Cell-surface Molecules	
	TT	VENIOCDAFTS	
	11.	XENOGRAFTS	
		A. Mechanisms of Response to Xenografts	
		B. Results of Xenotransplantation	
3	III.	MATERNO-FETAL RELATIONSHIPS	
		A. Immunogenetics	
		B. Infertility and Recurrent Abortion	
		C. Mechanisms of Maternal Tolerance	
	IV.	TUMOR IMMUNITY	
		A. Immunogenetics	
		B. Effects of Blood Transfusions	
	v	IMMUNOGENETICS AND HISTOCOMPATIBILITY	
	٧.	A. Molecular Genetics of the Human MHC and Its Products	
		B. Experimental Antigens of the Histocompatibility Systems	
		C. Antigenic Expression and Distribution	
		D. Kidney	
		1. Tissue Matching	
		2. Highly Sensitized Patients, Humoral Antibodies and Rejection, and Cross-matching	
		3. ABO Blood Group Incompatibility	
		E. Liver	
		F. Heart	
	VI	IMMUNOSUPPRESSION	
		A. Recipient Non-compliance.	
		B. Cyclosporine	
		Metabolism and Pharmacokinetics	
		Mechanisms of Action and Interactions.	
		3. Measurement and Monitoring	
		vvavve.vvt MIM ITVIIIIVI IIIB,	

(Continued on following page)

		4. Physiological Effects	915
		5. Nephrotoxicity	931
		6. Other Effects and Complications	946
		7. Adjunctive Therapy and Cyclosporine	956
	C.	Antithymocyte and Antilymphocyte Globulins	968
		Monoclonal Antibodies	977
		1. OKT3	977
		2. Anti-IL2 Receptor	992
		3. Anti-CD3, CD4, and Other	1013
		4. Mechanisms of Action	1036
	E	FK 506.	1042
		15-Deoxyspergualin	1076
		Lymphoid Irradiation.	1108
		Locally Applied Immunosuppression.	1120
		Other Immunosuppressive Agents	
		Blood Transfusion Effects	1130
			1165
	K.	Monitoring	1187
		Book II	
		DOOK II	
VII.	OR	GAN PROCUREMENT, PRESERVATION, AND EARLY FUNCTION	1195
		Techniques of Procurement	1197
		Kidney	1221
		Donor and Recipient Management	1221
		2. Cytoprotective Agents and Preservation	1240
		Mechanisms of Preservation Injury	1256
		4. Assessment of Organ Damage	1266
		5. Results	1274
	0		
	C.	Liver	1285
		1. Donor and Recipient Management	1285
		2. Cytoprotective Agents and Preservation	
		3. Mechanisms of Preservation Injury	1316
		4. Assessment of Organ Damage	1327
		5. Results	1342
		Experimental Heart and Heart/Lung Procurement and Preservation	1347
		Pancreas Preservation	1369
	F.	Blood Vessels Preservation	1384
VIII	OP	RGAN DONATION AND ALLOCATION	1391
v 111.	Or	SAN DONATION AND ALLOCATION	1391
IX.	KI	DNEY TRANSPLANTATION—CLINICAL	1425
		Immunosuppression for Clinical Transplantation	1446
		1. Cyclosporine	1446
		a. Metabolism and Pharmokinetics	1449
		i. Actions and Interactions	1453
		ii. Measurement and Monitoring	1462
		iii. Physiological Effects	1492
		iv. Nephrotoxicity	1508
		v. Other Effects and Complications	1558
		b. Clinical Trials and Results in Adults	1573
		i. Lymphocyte Responses	
			1573
15		ii. Immunosuppressive Manipulation	1575
		iii. Immunopathology of Renal Grafts	1670
		c. Clinical Trials and Results in Children	1683
		2. Azathioprine and Prednisone, Lymphocytophoresis, and Cyclophosphamide	1709
		3. Antithymocyte and Antilymphocyte Globulins	1726
		4. Monoclonal Antibodies	1738
		5. Donor Antigen Infusion	1787
		6. Lymphoid Irradiation	1790
		7. Blood Transfusion Effects	1802
	B.	Immunological Monitoring and Diagnosis of Rejection	1842

	Kidney Donors	
· D	Surgery of Kidney Transpiantation—Diagnosis and Management of Complications	1953
E	The Kidney Recipient	1967
	1. Management	
	2. Special Groups	
	a. Children	
	b. Black Recipients	
	c. Diabetics	
	d. Older Patients	2018
	e. High Risk Recipients	2026
	f. Recipients with Specific Diseases	2031
	3. Physiology and Pathology in Kidney Recipients	
	4. Complications of Kidney Transplantation	
	a. Viral Infections	
	b. Other Infections	
	c. Recurrent Disease	
	d. Vascular Complications	2134
	e. Gastrointestinal Complications	2143
	f. Skeletal Complications,	215
	g. Chronic Rejection	
F	Results and Registry Reports	
X. L	IVER TRANSPLANTATION—CLINICAL	219
	. Immunopathology	
	B. ABO Blood Group Incompatibility	
	Rejection and Blood Flow in Liver Transplantation	
D	). Immunosuppression	
	1. Cyclosporine	
	Antithymocyte and Antilymphocyte Globulins	2244
	3. Monoclonal Antibodies	224
E	. Infectious Complications	2260
	. Monitoring	
	From Techniques in Liver Transplantation Surgery	
U		
	1. Clinical	
	2. Experimental	
	I. Early Liver Function and Donor Factors	
I	I. Results	239
	1. Adult Recipients	239
	2. Children	
I	J. Biology of the Transplanted Liver	
K	Complications	
	1. Central Nervous System	
	2. Arterial	245
	3. Renal	246
	4. Biliary	247
	Book III	
I. H	EART, HEART/LUNG, AND LUNG TRANSPLANTATION	247
A	. Immunosuppression	247
	1. Azathioprine	
	2. Cyclosporine	
	3. OKT3	
	3. Infections	
C	C. Rejection and Monitoring	251
	D. Techniques in Cardiac Transplantation Surgery	
	2. Donor Studies	
	Biology of the Transplanted Heart	
G	. Complications	2579

	H. Heart/Lung Transplantation	2581
	1. Monitoring	2581
	2. Complications	2592
	I. Lung Transplantation	2594
	1. Techniques	2594
	2. Complications	2603
XII.	PANCREATIC ISLET TRANSPLANTATION	2605
	A. Autotransplantation	2617
	B. Isolation of Islets	2622
	C. Preservation	2635
	D. Fetal Pancreas Transplantation	2653
	E. Immunogenicity and Mechanisms of Rejection	2676
	F. Sites and Methods of Transplantation	2689
	G. Lymphokines and Cytokines	2697
	H. Prevention of Rejection and Effects of Immunosuppression	2703
	I. Antigenic Modulation, Enhancement, and Tolerance	2723
	J. Xenografts	2728
	K. Results	2744
	and the floring the contract of the contract o	
XIII.	PANCREATIC ORGAN TRANSPLANTATION	
	A. Organ Procurement	2765
	B. Immunosuppression	2769
	C. Monitoring	2771
	D. Surgical Techniques and Complications	2799
	E. Combined Renal and Pancreatic Transplantation	2831
	F. Results	2845
XIV.	TRANSPLANTATION OF THE SMALL INTESTINE	2869
VV	BONE MARROW TRANSPLANTATION	2915
A	A. Donor Graft Manipulation.	2934
	B. Recipient Conditioning	2952
	C. Hemopoietic Regulatory and Growth Factors.	2964
	D. Immunogenetics and Histocompatibility	2968
	E. Mechanisms of Engraftment and Rejection	2982
	F. Mechanisms and Manifestations of Graft-Versus-Host and Graft-Versus-Leukemia Reaction	2989
	G. Immunosuppressive Manipulation	3053
	H. Effects and Results	3058
	I. Complications: Viral Infections	3095
	J. Evolving Strategies	3112
	J. Evolving Strategies	3112
XVI.	TRANSPLANTATION OF THE CORNEA	3116
	A. Techniques, Effects, and Results	3133
		2150
XVII.	CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVE TRANSPLANTATION	3159
	A. Techniques, Effects, and Results	3171
	LIMB TRANSPLANTATION	3183
XIX.	URINARY BLADDER TRANSPLANTATION	3194
XX.	ORGAN TRANSPLANTATION AND CANCER	3197
	Index	
TUILINE	RINGA	2611

### CONTENTS

#### Book I

Foreword	
Presidential Address: The Legacy of Sir Peter Medawar	1
Oration	
Second Generation Transplantation Biology Through the Molecular Revolution	5
IMMUNOBIOLOGY OF TRANSPLANTATION	
Advances in the Understanding of Rejection Mechanisms	10
Pathology and Immunopathology of Solid Organ Graft Rejection	14
Human T-Cell Receptors	18
The Interleukins as Lymphocyte Growth Factors	22
The Mediators of Inflammation (Interleukin-1, Interferon-t, and Tumor Necrosis Factor) and Their Relevance to Rejection	26
Leukocyte Adhesion Molecules Involved in Inflammation Stephanie M. Dunn, Andrew J. Hillam, Frank Stomski, Boquan Jin, Carolyn M. Lucas, Andrew W. Boyd, Geoffrey W. Krissansen, and Gordon F. Burns	31
T-Cell Clones Recognizing MHC Products	35
The Role of Accessory Molecules in Lymphocyte Activation	38
The T-Lymphocyte CD2 Antigen—Genetic and Functional Studies	41
Molecular Analysis of FcR of T-Cells and Other Cell Types	44
Interleukin-1	46
Molecular Cloning and Biological Characterization of Human Interleukin-3 (IL-3)	50
Colony Stimulating Factor Receptors	54
Antiidiotypic Responses in the Suppression of Allograft Rejection	57
Tolerance and the Thymus J.F.A.P. Miller	59
The Use of Retroviral Vectors to Study Cell Transformation and Malignancy	61
Hemopoietic Growth Factor Gene Transfer	65

(Continued on following page)

#### CONTENTS

Immunopathology	
In Vivo Microscopy of Recirculation and Allograft Rejection in the Rabbit Ear-Chamber	67
Lymphokines	
Assessment of Production of Tumor Necrosis Factor α Under the Influence of Immunosuppressive Drugs  E. Dupont, L. Schandene, C. Denys, A. Crusiaux, and J. Wybran	70
Lymphokine Transcription in Vascularized Mouse Heart Grafts: Effects of "Tolerance" Induction R.P. Lowry, K. Wang, B. Vernooij, and D. Harcus	72
Recombinant Interleukin-4 and Partially Purified Low-Molecular-Weight B-Cell Growth Factor Stimulate Normal Resting Human T-Lymphocytes	74
Differential Cytokine Production by Natural Killer Cells and T-Cells of the αβ and the γδ T-Cell Receptor Classes H.S. Warren, A. Bezos, V. McPhun, R.G. Pembrey, W.E. Pullman, S. Elsbury, L. Preston, and A.J. Hapel	77
Time-Dependent Regulation of MHC Class II Antigens on Capillary Endothelium by TNF J.F.M. Leeuwenberg, G.M.A.A. Jeunhomme, C.J. Van der Linden, and W.A. Buurman	78
Interleukin-2 Reconstitutes Natural Killer Activity in Transplant Recipients F. Citterio, R. Cauda, U. Pozzetto, M. Tumbarello, F. Serino, L. Ortona, and M. Castagneto	80
Immune Signals Involved in Cyclosporine and Methylprednisolone Inhibition of A23187 Ionophore Induced Proliferation	82
Fc-Receptors Regulate Secretion of Tumor Necrosis Factor by Human Monocytes	84
Vcrapamil Selectively Inhibits Expression of Interleukin-2 Messenger RNA in Mitogen Activated Mononuclear Blood Cells	85
Role of Recombinant Interleukin-2 (rIL-2) and Large Granular Lymphocytes (LGLs) in Acute Rat Graft-Versus-Host Disease (GVHD)John Clancy, Jr., Joanna Goral, Elizabeth J. Kovacs, and Thomas Ellis	88
Incubation of T-Cell or Monocytic Cell Lines with 1, 25-Dihydroxyvitamin D3 Before Mitogen Potentiates IL-2 and IL-1 Beta mRNA Levels	90
Human Neutrophil Function and Immunoregulatory Serum Factors E.E. Etheredge, G.D. Frentz, B. Bedi, S. Hebbar, K.K. Koontz, K. Sullivan, and D. Thake	92
A Human-Mouse T-Cell Hybridoma-Derived Lymphokine Inhibits Thymidine Uptake of T-Lymphocytes  R. Laus and W. Muller-Ruchholtz	96
Differential Effects of Azathioprine (AZA), Cyclosporine A (CSA), and Dexamethasone (DEXA) on Lymphokine Mediated Inflammation (LMI) in Rejecting AllograftsJ. Mellert, U.T. Hopt, F. Erath, and H. Holzer	98
Receptor-Mediated Endocytosis of IL-2 by PHA Stimulated Lymphocytes Tee-Ping Lee and Basab K. Mookerjee	100
Cell-Surface Molecules	
Association of CD7 and CD3 Molecules on the T Cell Surface	103
A Common Trigger Molecule (TrgS) for Secretion of Lytic Factor is Expressed on Cells that Participate in non-MHC Restricted Cellular Cytotoxicity	105
Cross-Reactive Idiotypes in Human Alloreactive Antibodies? H. Hebart, B. Greger, U.T. Hopt, and W. Lauchart	108
Epithelial Cell Cultures and Determination of Surface Antigens (Class II Antigens in Mice) J. Fischer, G. Kirste, and H. Wilms	110

#### CONTENTS

(continued)

Phenotypic Analysis of CD3+ $\alpha/\beta$ TCR-Cells in Allograft Recip	ients and in Normal I vmphoid Tissue
Phenotypic Analysis of CD3+\alpha/\beta FCR-Cells in Allograft Recip  R. Sch	winzer, H.J. Schlitt, K. Wonigeit, and R. Pichlmayr 111
Induction of Ia Antigen Expression on Endothelium of Rat Vein  Michael L. Marin, Mark A. Hardy, Ronald	Allografts: Studies by Immunogold Labeling E. Gordon, Keith Reemtsma, and Alan I. Benvenisty 113
Monoclonal Antibodies Recognizing Shared Molecules on Endot	helial Cells and Leukocytes
Anti-Leu2a (Anti-CD8) Monoclonal Antibody Therapy: Antibody Fc-FcRII Interaction	
Human Monoclonal Antibodies to B Lymphocyte Cell Surface A Response	
Expression of Immune Cell Surface Markers in Vivo and Immun A. Kulkarni, W. Fanslow, I	
The Effect of Steroids on the Production of Non-IFN-y MHC Cl	E.E.M. Spronken, and W.A. Buurman 125
	Comparison of the Lifeer of Cyclesporne, Verapamil, and Tr
	Permeability of Mitochondria
Mechanisms of Immunobiological Reactions	Differential in Vice Function of Splet acres and Lymphocyte
Generation of Effector T-Cells Expressing Chimeric T-Cell Rece	ptor with Antibody Type-SpecificityG. Gross, G. Gorochov, T. Waks, and Z. Eshhar
Antigen Specific Effector Mechanisms in Skin Allograft Rejection	
Cross-Linking of Lyt-2 (CD8) to the T-Cell Antigen Receptor O	ptimally Activates T Lymphocytes
Survival of Cytotoxic T-Cell Clones (Tc) In Vivo and Their Abili Depleted Mice Eric S. Berens, Mark W. Shelton, Lindo	ity to Effect Skin Allograft Rejection in T-Cell
Studies of the Human and Rat Macrophage Receptor for Interle IL-2 Boosts Interleukin-1 Production by IL-2R + Macrophage	
Endogenous Peptides Contribute to the Ligand Recognized by A. G. Lombardi, S.	nti-DR1 Human Alloreactive T-Cells Sidhu, J.R. Lamb, J.R. Batchelor, and R.I. Lechler
Gamma-Interferon Induced Endothelial Cell Effects are Regulat	ed by Eicosanoids
Different Modes of T-Cell Activation by Monoclonal Antibodies	to the α/β T-Cell Receptor and the CD3 Complex  H.J. Schlitt, R. Schwinzer, and K. Wonigeit 147
The Relative Importance of Local Versus Systemic Immune Res	ponse in Allograft Rejection
Indirect Presentation of Alloantigen In Vivo	A. Mirisklavos, R.M. Sutherland, and W. Boyle 151
IgG-Anti-Immunoglobulin Induced by Immunization with Antib Suppression?	oody-Coated Blood Cells: Mechanism for B-Cell
Effector Mechanism of H-Y and Non-H-2 Incompatible Skin Gr	
Effect of HLA Class II Antigen on in Vitro and in Vivo Cellular	Responses N. Matsuno, N. Sano, T. Nakatsuji,
Differential Modulation of Macrophage Function by Allosensitiz  M.L. Jordan, A.	

(Continued on following page)